On June 3, 2014, Many investors appear to be quite bearish on VIVUS, Inc. (NASDAQ:VVUS) especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.97% of the float is sold short, suggesting an extreme level of bearishness for VVUS, according to Zack. VIVUS, Inc. (NASDAQ:VVUS) net profit margin is -64.60% and weekly performance is 7.00%. On last trading day company shares ended up $5.20. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is 0.82%.
On June 3, 2014, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -0.50% in last trading session and ended the day on $5.97. Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -14.47%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 1.64% to $6.80. The company on June 2 announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -1.05% in last trading session and was closed at $6.62, while trading in range of $6.61 – $6.86. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -2.93%.
MannKind Corporation (NASDAQ:MNKD) VP Juergen Martens sold 120,000 shares of the stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $11.00, for a total value of $1,320,000.00. Following the completion of the transaction, the vice president now directly owns 114,024 shares of the company’s stock, valued at approximately $1,254,264. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $10.70. Company weekly volatility is calculated as 8.12% and price to cash ratio as 116.15. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 18.49%.
Switzerland’s Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) on Monday agreed to buy Genia Technologies in hopes the target’s genetic sequencing technology may dramatically lower the price of identifying DNA while speeding sequencing. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) On last trading day company shares ended up $ 37.60 .
Leave a Reply